2020 Revenues ($USD) : $47,994,000,000
2020 R&D spend : $13,558,000,000
2020 Number of Employees : 74,000
Fiscal Year End : 12/31/2020
Key People : Kenneth C. Frazier, chair and CEO; Robert M. Davis, president, Merck & Co.; Sanat Chattopadhyay, EVP and president, Merck Manufacturing Division; Frank Clyburn, EVP and president, human health; Richard R. DeLuca Jr., EVP and president, Merck animal health; Dr. Julie Louise Gerberding, EVP and chief patient officer, strategic communications, global public policy, & population health; Dr. Dean Y. Li, EVP and president, Merck Research Laboratories; Caroline Litchfield, EVP and CFO; Steven C. Mizell, EVP and chief human resources officer; Dave Williams, chief information & digital officer; Jennifer Zachary, EVP, general counsel and corporate secretary

Merck is developing therapeutic and preventative drugs and vaccines for several conditions. Its development efforts extend to oncology, immunology, neurosciences, virology, cardiovascular, diabetes and women's health. Despite the COVID-19 pandemic, the Kenilworth, N.J.-based pharma giant has made numerous acquisition announcements in the last year to expand its oncology and autoimmune disease treatment portfolios. It acquired Themis for an undisclosed amount in June 2020; OncoImmune for $425 million in November 2020; VelosBio for $2.75 billion in November 2020 and Pandion Therapeutics for $1.85 billion in February 2021. The company has also played a role in the pandemic. It helped J&J produce its COVID-19 vaccine and received funding from BARDA to expand its manufacturing capacity for COVID-19 vaccines and medicines. –DK